Overview
Cara Care creates digital therapeutic solutions for digestive health by offering a mobile app that delivers a personalized, multi-therapy program for IBS, IBD, and GERD. The app combines nutritional therapy, therapy from certified psychologists, and a digital diary to track symptoms and diet, guiding users through individualized plans with data-driven updates backed by clinical studies on reducing IBS symptoms. In Germany, the program is a DiGA prescription medical device reimbursed by statutory health insurances, and the company has both German and U.S. offerings, supported by significant investments from Dr. Schär and Johnson & Johnson Innovation. Its goal is to make evidence-based digestive care more accessible and effective for long-term symptom management while expanding internationally and continuing clinical validation.
Work here?Claim your company
Simplify's take
What believers are saying
- August 31, 2026 Android updates show the core German product remains actively maintained.
- Bayer's December 2024 acquisition gives Cara Care a larger sales, regulatory, and distribution machine.
- Permanent German reimbursement broadens patient access and supports repeat prescribing through 90-day cycles.
What critics are saying
- The English tracker froze in October 2020, signaling weak non-prescription product stewardship.
- German revenue depends on GKV-SV reimbursement; any DiGA price reset hits margins fast.
- Bayer can shelve Cara Care after acquisition if IBS economics disappoint; that ends the franchise.
What makes Cara Care unique
- Cara Care pairs CBT, diet, and hypnosis in one BfArM-approved IBS therapy.
- On November 2026, Germany granted permanent reimbursement after GKV-SV price talks.
- Its regulated DiGA status creates prescription access unavailable to ordinary wellness apps.
Help us improve and share your feedback! Did you find this helpful?